Novartis' Phase 3 V MONO Study For Twice-yearly Leqvio (Inclisiran) Met Its Primary Endpoints Showing Leqvio Monotherapy Lowered Low-density Lipoprotein Cholesterol Versus Placebo And Ezetimibe In Patients Who Were At Low Or Moderate Risk Of Developing Atherosclerotic Cardiovascular Disease And Not Receiving Lipid-lowering Therapy
Portfolio Pulse from Benzinga Newsdesk
Novartis' Phase 3 V MONO study for Leqvio (Inclisiran) met its primary endpoints, showing effectiveness in lowering LDL cholesterol compared to placebo and ezetimibe in patients at low or moderate risk of atherosclerotic cardiovascular disease.
August 28, 2024 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Leqvio (Inclisiran) successfully met primary endpoints in a Phase 3 study, demonstrating its effectiveness in lowering LDL cholesterol in patients at low or moderate risk of cardiovascular disease.
The successful Phase 3 trial results for Leqvio (Inclisiran) are likely to positively impact Novartis' stock as it demonstrates the drug's effectiveness, potentially leading to increased market adoption and revenue growth.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90